Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3372689 (Ceperognastat) OGA Occupancy PET Study
NCT03944031Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ceperognastat in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Primary endpoint: Percent O-GlcNAcase Enzyme Occupancy. Started May 2019; status: completed.
02
Drugs
ceperognastat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03944031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03944031.